Clinical trial
Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody…
NCT02163577 · Kyowa Kirin, Inc., Industry · Completed
Key facts
| NCT number | NCT02163577 |
|---|---|
| Title | Study of KRN23 (Burosumab), a Recombinant Fully Human Monoclonal Antibody Against Fibroblast Growth Factor 23 (FGF23), in Pediatric Subjects With X-linked Hypophosphatemia (XLH) |
| Official title | A Randomized, Open-Label, Dose Finding, Phase 2 Study to Assess the Pharmacodynamics and Safety of the Anti-FGF23 Antibody, KRN23, in Pediatric Patients With X-linked Hypophosphatemia (XLH) |
| Lead sponsor | Kyowa Kirin, Inc., Industry |
| Collaborators | Kyowa Kirin Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | X-linked Hypophosphatemia |
| Intervention type | Biological |
| Interventions | burosumab |
| Enrollment | 52 |
| Start date | Jul 2, 2014 |
| Primary completion | Oct 30, 2018 |
| Completion | Oct 30, 2018 |
| First posted | Jun 13, 2014 |
| Last update posted | May 6, 2024 |
| Countries | France, Netherlands, United Kingdom, United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: